Teamwork to Make the CGD Treatment Dream Work

There’s been a lot of talk in recent years about interdisciplinary projects. The idea is to put together people with different skillsets to address problems. The goal is for everyone to use their knowledge and experience to cross the divide to help solve problems in different fields. These partnerships can be particularly useful when it comes to medicine.

An example can be seen in the teaming up of MaxCyte, Inc. and the United States National Institute of Allergy and Infectious Diseases (NIAID) to create new ideas to fight chronic granulomatous disease (CGD).
This rare genetic disorder weakens the immune system’s ability to fight off bacterial infections. Essentially, the only current treatment for CGD is bone marrow transplantation from a similar, but not identical, donor. This type of transplant is riskier than self-transplants and exact match transplants due to the risk of rejection.

MaxCyte and NIAID are working with the Flow Electroporation™ Platform and the newest genetic technology—CRISPR/Cas9—to develop a new treatment option for people with CGD. CRISPR uses enzymes and RNA strains to target and edit damaged or mutated parts of the genome. CRISPR is expected to be able to edit the genetic code effectively while the Flow Electroporation Platform is needed to scale up and deliver the necessary effect.

MaxCyte has received research grants in the past to develop stem cell therapies. MaxCyte and NIAID have previously teamed up to develop treatment options for sickle cell disease. Both agencies in this partnership are bringing what they do best to solve the problem together.
Let’s hope they successfully bring a treatment for CGD to market soon. Click here to read a press release about the partnership from the PR Newswire.

Share this post

Share on facebook
Share on google
Share on twitter
Share on linkedin
Share on pinterest
Share on print
Share on email